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Current systems for the evaluation of trauma severity are tedious and diﬃcult to apply in an actual 
emergency setting.  We aimed to develop and assess the accuracy of a more eﬃcient severity evalua-
tion system,  termed the Ugawa classiﬁcation,  using brain-type natriuretic peptide (BNP) measurement 
and the estimated glomerular ﬁltration rate (eGFR).  Two-hundred trauma patients were divided into 
2 groups using an eGFR cut-oﬀ value of 90ml/min/1.73m2 as an indicator of normal renal function and 
2 additional groups according to whether the BNP values were greater or less than the age in years.  
This resulted in 4 subject groups with diﬀerent combinations of eGFR and BNP.  The mean SOFA 
score,  injury severity scores (ISS),  trauma and injury severity scores (TRISS),  and Acute Physiology 
and Chronic Health Evaluation II (APACHE II) scores of the groups were compared by Kruskal-
Wallis test,  and the mortality rate after 90 days was calculated.  Signiﬁcant intergroup diﬀerences 
were found in SOFA scores,  ISS scores,  and APACHE II-predicted mortality rates.  Although no sig-
niﬁcant diﬀerences were found in the mortality rate after 90 days or TRISS-predicted mortality rate 
among the 4 groups,  there was a trend toward increasing trauma severity from group 1 to 4.  Thus,  
the Ugawa classiﬁcation is as accurate as existing systems,  has greater eﬃciency,  and is user-friendly.
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he initial treatment choice for patients with 
severe trauma must be determined within min-
utes and early intervention provided accordingly.  The 
predicted reserve respiratory capacity,  circulation 
dynamics,  and renal function during the initial acute 
stage are important indicators in selecting a therapeu-
tic strategy during the acute phase.  While reserve 
respiratory capacity is relatively easy to estimate by 
reviewing physiological ﬁndings during the acute 
treatment stage,  biomonitoring,  blood gas analysis,  
and detailed evaluation of heart and renal function are 
diﬃcult.
　 To assist in determining the strategy for early 
intervention,  various scoring systems for the evalua-
tion of severity have been developed,  including the 
injury severity score (ISS),  the sequential organ 
failure assessment (SOFA) score,  the trauma and 
injury severity score (TRISS),  and the Acute 
Physiology and Chronic Health Evaluation II 
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(APACHE II) score.  However,  it is diﬃcult to objec-
tively evaluate the severity of injury in an actual 
emergency setting using these complex systems [1-3].  
In addition,  the continuous monitoring of respiratory 
status,  circulation dynamics,  and renal function to 
provide life support is also a challenge in these set-
tings.  Thus,  the development of a simple yet accurate 
system for evaluating the severity of injury is critical 
to facilitate the selection of a treatment strategy.
　 The utility of the brain-type natriuretic peptide 
(BNP) value for evaluation of heart failure has been 
widely reported [4-15].  Because the BNP value is 
aﬀected by renal function and age,  renal function is 
evaluated and age is considered during BNP measure-
ment [16-24].  Regarding its use in assessing injury 
patients,  several studies have examined the utility of 
BNP measurement for assessing patients with sus-
tained solitary head injury [25-28] and extensive burn 
injury [29,  30].  However,  there have been very few 
studies on the utility of BNP values speciﬁcally for 
patients with severe trauma,  including those who have 
sustained multiple injuries [31].  To ﬁll this research 
gap,  we evaluated the severity of trauma in patients 
with acute injury using the BNP value as an indicator 
of heart function and the estimated glomerular ﬁltra-
tion rate (eGFR) as an indicator of renal function.  
Based on the results,  we developed a new severity 
classiﬁcation system for patients with severe trauma.  
We then used this system to predict the mortality rate 
after 90 days and compared its accuracy to that of 
existing severity evaluation systems.
Methods
　 All trauma patients (n＝208) who had been trans-
ferred to the emergency intensive care unit (EICU) of 
the advanced critical care center of Okayama University 
Hospital between March 1,  2012 and August 31,  
2013 were included in this study.  These 208 patients 
included patients who had experienced high-energy 
injuries,  multiple injuries,  extensive burn injuries,  
and extremity amputation.  Exclusion criteria were 
traumatic cardiopulmonary arrest at the time of trans-
fer (2 patients),  withdrawal from treatment because of 
irreversible central nervous system damage (i.e.,  brain 
death) (2 patients),  serious extensive burns from a 
suicide attempt and refusal of informed consent by the 
family (1 patient),  and age＜18 years (3 patients).  
Thus,  the ﬁnal sample consisted of 200 subjects (133 
men and 67 women) with a mean age of 49.67 years 
(age range,  18-98 years; median: 50 years).
　 For each of the 200 trauma patients in the ﬁnal 
subject group,  we calculated the regression curves for 
BNP and age and for BNP and eGFR,  and found that 
the BNP levels tended to increase with advancing age 
and decreasing eGFR (p＜0.05,  Fig.  1A and B).  This 
suggested that BNP is associated with both age and 
eGFR.  The subjects were then divided into 2 groups 
based on a cut-oﬀ value of eGFR＝90ml/min/1.73m2 
as an indicator of normal renal function [32].  The 
subjects were also divided into 2 other groups,  a 
BNPｧage and a BNP＜age group,  using BNP as an 
indicator of heart function.  Then,  each patient was 
assigned to one of the following 4 groups based on 
their combination of BNP and eGFR group 
assignments: group 1,  eGFRｧ90ml/min/1.73m2 and 
BNP＜age; group 2,  eGFR＜90ml/min/1.73m2 and 
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Fig. 1　 Regression analysis.  A,  Regression curve for BNP and 
age; B,  Regression curve for BNP and eGFR.
BNP＜age; group 3,  eGFRｧ90ml/min/1.73m2 and 
BNPｧage; and group 4,  eGFR＜90ml/min/1.73m2 
and BNPｧage (Table 1).  We set the cutoﬀ value for 
BNP based on age because a universal BNP cutoﬀ 
value for injured patients is not available and BNP is 
known to be aﬀected by age [21-24].  We designated 
this classiﬁcation the Ugawa classiﬁcation system.  
The mean SOFA score,  mean ISS score,  APACHE 
II-predicted and TRISS-predicted mortality rates of 
the groups were compared using the Kruskal-Wallis 
test for the identiﬁcation of statistical diﬀerences,  
and the mortality rate was calculated after 90 days for 
each group.
　 Data for age,  sex,  disease severity,  disease his-
tory and treatment progression,  laboratory blood 
parameters,  prognosis,  and presence of delayed 
eﬀects were extracted from the medical records and 
archives of our advanced critical care center and 
analyzed.  Any personal information appearing with 
data extracted from the medical records was removed 
and replaced with a number to maintain patient pri-
vacy.  Before study initiation,  all patients provided 
signed informed consent,  which was posted publicly on 
the hospitalʼs announcement board and the departmen-
tal homepage on the hospital website.  The Okayama 
University Hospital Ethical Review Board reviewed 
and approved the study aims and procedures.
Results
　 Among the 200 patients,  the mortality rate after 
90 days was 6.0ｵ; the mean ISS,  18.20; the mean 
SOFA score,  3.09; the mean TRISS-predicted mor-
tality rate,  17.22ｵ; and the mean APACHE 
II-predicted mortality rate,  17.1ｵ.  The mean SOFA 
score was signiﬁcantly diﬀerent between the eGFRｧ
90ml/min/1.73m2 and eGFR＜90ml/min/1.73m2 
groups (2.51 [SE＝0.251] vs. 3.47 [SE＝0.232];  
p＜0.01).  In contrast,  the diﬀerence between the 
groupsʼ mortality rates was not signiﬁcant (3.7ｵ vs. 
6.7ｵ).  The mean SOFA score of the BNP＜age 
group was 2.86 [SE＝0.173] compared to 4.51 [SE
＝0.604] in the BNPｧage group (p＜0.01).  In con-
trast,  the diﬀerence between the groupsʼ mortality 
rates,  which were 4.1ｵ and 7.4ｵ,  respectively,  was 
not found to be signiﬁcant (Fig.  2).
　 These results indicate that a more serious degree 
of organ disorder was experienced in the eGFR＜90 
ml/min/1.73m2 group and the BNPｧage group.  
Based on these results,  the patients were divided into 
4 groups as shown in Table 1 (Ugawa classiﬁcation).
　 The mortality rate was 2.67ｵ in group 1,  8.1ｵ in 
group 2,  14.3ｵ in group 3,  and 15.79ｵ in group 4.  
Although no signiﬁcant diﬀerences were found among 
the groups in the mortality rate after 90 days (p＝
0.162),  the mortality rate showed an increasing trend 
from groups 1 to 4.  Statistical comparison of the 
Ugawa classiﬁcation to the currently used severity 
assessment tools revealed that there were no signiﬁ-
cant diﬀerences in the TRISS-predicted mortality rate 
among the 4 groups (p＝0.086),  but signiﬁcant inter-
group diﬀerences in the SOFA score (p＜0.01),  ISS 
(p＜0.01),  and APACHE II-predicted mortality rate 
(p＜0.01; Table 2).
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Fig. 2　 Classiﬁcation of SOFA score and mortality rate based on 
eGFR and BNP values.  SOFA values indicate mean scores and 
mortality rates are shown in %.  BNP,  brain-type natriuretic peptide;  
eGFR,  estimated glomerular ﬁltration rate; SOFA,  sequential organ 
failure assessment.
Table 1　 Ugawa classiﬁcation according to BNP and eGFR val-
ues
Ugawa classiﬁcation BNP (pg/ml) eGFR (ml/min/1.73m2)
1 ＜Patientʼs age ｧ90
2 ＜Patientʼs age ＜90
3 ｧPatientʼs age ｧ90
4 ｧPatientʼs age ＜90
BNP,  brain-type natriuretic peptide; eGFR,  estimated glomerular 
ﬁltration rate.
Discussion
　 Among the four groups examined in this study,  all 
the severity scores and the mortality rate after 90 
days were lowest in group 1.  However,  the mean ISS 
and TRISS-predicted mortality rate in group 1 were 
14.21 and 11.83ｵ,  respectively,  suggesting that the 
patients in this group had sustained severe injury.  In 
group 2,  the mean ISS was 21.46,  which was the 
highest value among all the groups,  and the APACHE 
II-predicted mortality rate was 18.88ｵ,  which was the 
second highest value among the groups,  but the mor-
tality rate after 90 days (8.1ｵ) was relatively low.  
This ﬁnding can be attributed to the initially normal 
heart and renal function in patients in group 2,  as well 
as their greater likelihood of sustaining severe trauma 
because of a high level of activity,  resulting in a lower 
eGFR value due to severe trauma.  In addition,  
because the lowest value within 24h of EICU admis-
sion－the most severe phase of patient presentation－
is the value used for calculating the APACHE 
II-predicted mortality rate,  this value was relatively 
high [33].  The results indicate that,  compared to the 
ISS and APACHE II scores,  Ugawa classiﬁcation is 
a more accurate means of determining the prognosis of 
patients with severe trauma.
　 While group 3 had a mean ISS of 16.00,  which was 
the third highest value among the 4 groups,  the mor-
tality rate after 90 days was 14.3ｵ,  which,  being the 
second highest,  was relatively high.  The APACHE 
II-predicted mortality rate of this group was 13.53ｵ,  
which was not signiﬁcantly diﬀerent from the actual 
mortality rate.  In group 3,  only patients with an 
abnormal BNP value were predicted to have low heart 
reserve capacity.  In addition to a mean ISS of 16,  
which suggests a high level of damage,  cardiovascular 
system failure occurred with treatment progression in 
patients with a low heart reserve capacity,  resulting 
in a high mortality rate of 14.3ｵ.
　 Comparison of groups 2 and 3 revealed that group 
2 had a lower mortality rate,  despite its high mean 
ISS score.  For patients in group 2,  the circulating 
blood volume was reduced due to hemorrhage;  
therefore,  they had lower eGFR values.  By using the 
Ugawa classiﬁcation as an index during initial treat-
ment,  ﬂuid resuscitation and hemostasis with aggres-
sive infusion and blood transfusion could be initiated 
promptly and serve as key lifesaving measures for 
these patients.  On the other hand,  an important con-
sideration is that patients in group 3 could have had a 
poor heart function from treatment initiation.  Thus,  
in addition to early hemostasis,  infusion and blood 
transfusion could be promptly initiated to avoid exces-
sive water load.  Prognosis would have been expected 
to improve with the provision of this circulatory sup-
port.
　 Group 4 had the highest mortality rate after 90 
days as well as the highest SOFA score and both 
TRISS- and APACHE II-predicted mortality rates.  
This group had a mean ISS of 17.79,  the second high-
est value.  Review of these results indicates that 
patients classiﬁed into group 4 during the initial treat-
ment experience had reduced heart and renal function 
from treatment initiation and had sustained fatal 
injury.
　 In this study,  the SOFA score,  ISS,  and APACHE 
II-predicted mortality rate were found to diﬀer sig-
niﬁcantly among the 4 study groups.  While no signiﬁ-
cant intergroup diﬀerences were found in the mortality 
rate after 90 days or in the TRISS-predicted mortal-
ity rate,  an increasing trend was seen from group 1 to 
4.  A strong correlation was observed between the 
Ugawa classiﬁcation and TRISS-predicted mortality 
and mortality after 90 days,  although this did not 
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Table 2　 Severity scores and mortality rate after 90 days
Group 1 Group 2 Group 3 Group 4 p-value
SOFA score  2.34 3.2  3.28  5.34 ＜0.01
ISS 14.21 21.46 16 17.79 ＜0.01
APACHE II score 12.03 18.88 13.53 29.4 ＜0.01
TRISS score 11.83 19.48 20.1 25.34 0.086
Mortality rate after 90 days  2.67 8.1 14.3 15.79 0.162
SOFA,  sequential organ failure assessment; ISS,  injury severity score; APACHE II,  Acute Physiology and Chronic Health Evaluation 
II; TRISS,  trauma and injury severity score.
reach statistical signiﬁcance.  We anticipate that future 
studies including a larger number of cases will reveal 
a signiﬁcant diﬀerence.  Use of the Ugawa classiﬁca-
tion to determine an appropriate therapeutic strategy 
accompanied by rapid and appropriate intervention 
may thus improve the survival rate.
　 In addition to accuracy,  the Ugawa classiﬁcation 
for severity evaluation oﬀers the advantages of eﬃ-
ciency and simplicity compared to the other complex 
scoring systems,  as it requires only 15 min to perform 
from initial blood sampling.  Particularly in group 2,  
the Ugawa classiﬁcation more accurately reﬂected the 
actual mortality rate compared to mortality-rate pre-
diction by the APACHE II system.  This ﬁnding sug-
gests that patients in group 2 who survive after the 
acute trauma period can be useful for eﬀective prog-
nosis,  which can be improved by investing in health-
care with adequate planning and improvement in the 
quality of care.  Furthermore,  the measurement and 
assessment of eGFR and BNP values are critical not 
only when designing an initial treatment strategy but 
also throughout the treatment.  The tool also suggests 
that monitoring of the patientʼs general condition and 
renal and heart functions are critical for survival.
　 In conclusion,  we developed the Ugawa classiﬁca-
tion tool for evaluating the severity of trauma using 
BNP and eGFR values.  The tool is as accurate as the 
existing severity evaluation tools and has the advan-
tages of simplicity and eﬃciency.  Because it requires 
only blood sampling for severity prediction,  this 
assessment tool would be particularly useful in outpa-
tient clinics with limited time and resources.
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